Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $19
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $15 to $19.
Stocks · News reference
Fulgent Genetics Lowers FY2026 Adj EPS Guidance from $(1.59) to $(2.35)-$(2.22) vs $(1.55) Est; Lowers FY2026 Sales Guidance from $350.000M to $330.000M-$340.000M vs $351.900M Est
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Fulgent Genetics shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY2026 adjusted EPS and FY2026 sales guidance.
Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analyst estimates for Q3. Other stocks also dip in pre-market.